PYPD: Wutah bathi EPS kuartalan PolyPid

PolyPid Ltd. (PYPD) risks facing regulatory rejection and a funding shortage amid intensifying competition. Meanwhile, surgeons value PolyPid Ltd. for its innovative extended-release antibiotic delivery systems. Production is automated via PLEX conveyors, eliminating manual labor. The quarterly EPS growth history helps determine the asset's fundamental floor, with the latest mark standing at 55.40.

PolyPid Ltd (PYPD) - Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan saka 04.07.2022 nganti 10.11.2026

Ringkesan rincian data analitis PolyPid Ltd. (PYPD)

- rega saham lan prakiraan rega para ahli:

Rega saham polypid.com|PYPD - Bagan tingkat prakiraan

- informasi kapitalisasi pasar:

Kapitalisasi pasar PolyPid Limited|PYPD - Total Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Buku saben Saham PolyPid|PYPD - Aset Bersih Perusahaan|Rasio Kapitalisasi marang Aset Bersih polypid.com|PYPD - Aset Agregat Bisnis

- data liabilitas lan likuiditas perusahaan:

Total Utang marang Modal PolyPid Ltd.|PYPD - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas polypid.com|PYPD - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku PolyPid Limited|PYPD - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan PolyPid|Likuiditas cepet polypid.com

- indikator bathi lan kelipatan valuasi:

PYPD - Bathi sawise pajeg|Bathi sing dikarepake PolyPid Ltd.|PYPD - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep polypid.com|PYPD - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan PolyPid Limited|PYPD - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan PolyPid|PYPD - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan polypid.com|PYPD - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep PolyPid Ltd.

Analisis komprehensif perusahaan:PolyPid Ltd.

PolyPid Ltd. is characterized by a critical dependence on FDA approval for the D-PLEX drug and a high risk of capital burn. The current value of 55.40 reflects the dynamics of net earnings per share, measuring the business's ability to generate real income amid clinical trials, which allows for an assessment of the company's resilience to shocks through the quarterly EPS growth trend and helps avoid overpaying for the asset.

Pesaing wigati